Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this phase II study is to determine the efficacy of fenretinide in the treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular degeneration (AMD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sirion Therapeutics, Inc.
• Collaborator: ReVision Therapeutics, Inc.
• Treatments: Fenretinide

Criteria

Inclusion Criteria:

• males or females, 50 to 89 years of age

• must have GA from AMD in one or both eyes

Exclusion Criteria:

• GA due to any disease other than AMD (eg, drug-induced)